Safety and Efficacy of Secukinumab Compared to Etanercept in Subjects With Moderate to Severe, Chronic Plaque-Type Psoriasis

Inclusion Criteria: * Subjects with chronic, plaque-type psoriasis for at least 6 months * Must have moderate to severe psoriasis based on PASI greater than 12, IGA greater than 3, and greater than 10% body surface area * Must be inadequately controlled by prior treatments (topicals, phototherapy, and/or systemic therapies) Exclusion Criteria: * Forms of psoriasis other than chronic, plaque-type (such as pustular, erythrodermic and guttate psoriasis) * Drug induced psoriasis * Use of other psoriasis treatments during the study * Prior use of etanercept * Prior use of secukinumab or any other drug that target IL-17 (interleukin 17) or the IL-17 receptor * Pregnant or lactating women; women who do not agree to use contraception during the study and for 16 weeks after stopping treatment * Significant medical problems such as uncontrolled high blood pressure, congestive heart failure, etc. * History of an ongoing, chronic or recurrent infection or evidence of tuberculosis * Allergy to rubber or latex Other protocol-defined inclusion/exclusion criteria may apply